432 related articles for article (PubMed ID: 9767427)
41. Development of two novel nontoxic mutants of Escherichia coli heat-labile enterotoxin.
Park EJ; Chang JH; Kim JS; Chung SI; Yum JS
Exp Mol Med; 1999 Jun; 31(2):101-7. PubMed ID: 10410310
[TBL] [Abstract][Full Text] [Related]
42. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.
Ryan EJ; McNeela E; Murphy GA; Stewart H; O'hagan D; Pizza M; Rappuoli R; Mills KH
Infect Immun; 1999 Dec; 67(12):6270-80. PubMed ID: 10569737
[TBL] [Abstract][Full Text] [Related]
43. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity.
Lycke N; Tsuji T; Holmgren J
Eur J Immunol; 1992 Sep; 22(9):2277-81. PubMed ID: 1381311
[TBL] [Abstract][Full Text] [Related]
44. Intranasal immunization using the B subunit of the Escherichia coli heat-labile toxin fused to an epitope of the Bordetella pertussis P.69 antigen.
Lipscombe M; Charles IG; Roberts M; Dougan G; Tite J; Fairweather NF
Mol Microbiol; 1991 Jun; 5(6):1385-92. PubMed ID: 1724057
[TBL] [Abstract][Full Text] [Related]
45. B subunit of E. coli enterotoxin as adjuvant and carrier in oral and skin vaccination.
Fingerut E; Gutter B; Goldway M; Eliahoo D; Pitcovski J
Vet Immunol Immunopathol; 2006 Aug; 112(3-4):253-63. PubMed ID: 16701905
[TBL] [Abstract][Full Text] [Related]
46. Expression and immunogenicity of enterotoxigenic Escherichia coli heat-labile toxin B subunit in transgenic rice callus.
Kim TG; Kim BG; Kim MY; Choi JK; Jung ES; Yang MS
Mol Biotechnol; 2010 Jan; 44(1):14-21. PubMed ID: 19657748
[TBL] [Abstract][Full Text] [Related]
47. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
[TBL] [Abstract][Full Text] [Related]
48. Functional pentameric formation via coexpression of the Escherichia coli heat-labile enterotoxin B subunit and its fusion protein subunit with a neutralizing epitope of ApxIIA exotoxin improves the mucosal immunogenicity and protection against challenge by Actinobacillus pleuropneumoniae.
Kim JM; Park SM; Kim JA; Park JA; Yi MH; Kim NS; Bae JL; Park SG; Jang YS; Yang MS; Kim DH
Clin Vaccine Immunol; 2011 Dec; 18(12):2168-77. PubMed ID: 22030372
[TBL] [Abstract][Full Text] [Related]
49. Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides.
Partidos CD; Salani BF; Pizza M; Rappuoli R
Immunol Lett; 1999 Apr; 67(3):209-16. PubMed ID: 10369128
[TBL] [Abstract][Full Text] [Related]
50. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants.
Douce G; Turcotte C; Cropley I; Roberts M; Pizza M; Domenghini M; Rappuoli R; Dougan G
Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1644-8. PubMed ID: 7878032
[TBL] [Abstract][Full Text] [Related]
51. Dendritic Cell-Mediated Mechanisms Triggered by LT-IIa-B
Lee CH; Hajishengallis G; Connell TD
J Microbiol Biotechnol; 2017 Apr; 27(4):709-717. PubMed ID: 28144014
[TBL] [Abstract][Full Text] [Related]
52. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.
Douce G; Giannelli V; Pizza M; Lewis D; Everest P; Rappuoli R; Dougan G
Infect Immun; 1999 Sep; 67(9):4400-6. PubMed ID: 10456880
[TBL] [Abstract][Full Text] [Related]
53. The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skin.
Beignon AS; Briand JP; Rappuoli R; Muller S; Partidos CD
Infect Immun; 2002 Jun; 70(6):3012-9. PubMed ID: 12010992
[TBL] [Abstract][Full Text] [Related]
54. [Expression and characterization of transcutaneous immunization adjuvant LTB and LTK63].
Chen SY; Yi Y; Guo Y; Bi SL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Mar; 20(1):8-11. PubMed ID: 16642208
[TBL] [Abstract][Full Text] [Related]
55. Structural basis for differential receptor binding of cholera and Escherichia coli heat-labile toxins: influence of heterologous amino acid substitutions in the cholera B-subunit.
Bäckström M; Shahabi V; Johansson S; Teneberg S; Kjellberg A; Miller-Podraza H; Holmgren J; Lebens M
Mol Microbiol; 1997 May; 24(3):489-97. PubMed ID: 9179843
[TBL] [Abstract][Full Text] [Related]
56. Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC).
Norton EB; Branco LM; Clements JD
PLoS One; 2015; 10(8):e0136302. PubMed ID: 26305793
[TBL] [Abstract][Full Text] [Related]
57. Construction, purification and immunogenicity of antigen-antibody-LTB complexes.
Green EA; Botting C; Webb HM; Hirst TR; Randall RE
Vaccine; 1996 Jul; 14(10):949-58. PubMed ID: 8873387
[TBL] [Abstract][Full Text] [Related]
58. Enhanced expression of B-subunit of Escherichia coli heat-labile enterotoxin in tobacco by optimization of coding sequence.
Kang TJ; Han SC; Jang MO; Kang KH; Jang YS; Yang MS
Appl Biochem Biotechnol; 2004 Jun; 117(3):175-87. PubMed ID: 15304769
[TBL] [Abstract][Full Text] [Related]
59. Enhanced mucosal immunogenicity of prion protein following fusion with B subunit of Escherichia coli heat-labile enterotoxin.
Yamanaka H; Ishibashi D; Yamaguchi N; Yoshikawa D; Nakamura R; Okimura N; Arakawa T; Tsuji T; Katamine S; Sakaguchi S
Vaccine; 2006 Apr; 24(15):2815-23. PubMed ID: 16446015
[TBL] [Abstract][Full Text] [Related]
60. Vaccine and adjuvant activity of recombinant subunit B of E. coli enterotoxin produced in yeast.
Fingerut E; Gutter B; Meir R; Eliahoo D; Pitcovski J
Vaccine; 2005 Sep; 23(38):4685-96. PubMed ID: 15951067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
